Winners and losers of the GLP-1 weight-loss drug boom in the global economy
The boom in GLP-1 weight-loss drugs is reshaping consumer habits and the corporate agenda. According to Gallup, about 38 million people in the United States were taking them in June, and PwC estimates around 5% of adults in the UK use them. Gyms, supplements and airlines see opportunities, while packaged food, fast food and fashion face falling spending. More than 200 listed companies outside healthcare mentioned these drugs in their quarterly earnings presentations.
In 45 seconds
- Gyms and supplements gain: GLP-1 users increased cardiovascular exercise by 36% and spend 20% more on supplements, according to PwC and BCG.
- Airlines: a 10% reduction in passenger weight would save the four largest US carriers US$580 million a year, according to Jefferies.
- Packaged food and fashion lose: spending on sweets fell 9% and on salty snacks 11% in the first six months of treatment, according to Cornell and Numerator.
Read the full story at La República
IASummary generated by artificial intelligence from a story by La República. It may contain errors: the original source prevails.
Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.